-
681
-
682
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in pat...
Published 2023-01-01“…This phase 1 study evaluated intravenous V937±pembrolizumab in patients with advanced solid tumors.Methods Patients had advanced non-small cell lung cancer (NSCLC), urothelial cancer, metastatic castration-resistant prostate cancer, or melanoma in part A (V937 monotherapy), and metastatic NSCLC or urothelial cancer in part B (V937+pembrolizumab). …”
Get full text
Article -
683
-
684
-
685
-
686
Geography and age drive racial and ethnic disparities in hospital mortality for paediatric community-acquired pneumonia in the United States: a retrospective population based cohor...
Published 2025-02-01“…Findings: Among 783,744 patients (median age 4 years [interquartile range 1–9 years], 45.9% female) with CAP, the overall mortality rate was 0.9%. …”
Get full text
Article -
687
Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses...
Published 2024-07-01“…Objective We report post hoc analyses of efficacy with first-line avelumab plus axitinib or sunitinib according to baseline neutrophil-to-eosinophil ratio (NER) in patients with advanced renal cell carcinoma (aRCC) from the JAVELIN Renal 101 phase 3 trial.Methods and analysis Progression-free survival (PFS), overall survival (OS) and objective response per baseline NER were analysed in the overall population and in patients with programmed death ligand 1 (PD-L1+) tumours. …”
Get full text
Article -
688
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with...
Published 2018-09-01“…Pooling analysis presented no systematic bias when comparing treatment effects of both assessments (ORR: OR=1.02 (95% CI 0.97 to 1.07), p=0.42, I2=0%; DCR: OR=0.97 (95% CI 0.92 to 1.03), p=0.32, I2=0%); PFS: HR=1.01 (95% CI 0.99 to 1.02), p=0.32, I2=0%; TTP: HR=1.04 (95% CI 0.95 to 1.14), p=0.37, I2=0%), regardless of funding source, mask, region, tumour type, study design, number of enrolled patients, response assessment criteria, primary endpoint and trials with statistically consistent/inconsistent inferences. …”
Get full text
Article -
689
Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients wi...
Published 2021-01-01“…Results. Thirty-one patients were analyzed. BNP and E/E′ improved, with BNP levels declining from 36.8±30.5 pg/mL to 26.3±25.9 pg/mL (p=0.0014) and E/E′ dropping from 12.7±4.7 to 11.0±3.3 (p=0.0376). …”
Get full text
Article -
690
Polymerized-Type I Collagen Downregulates Inflammation and Improves Clinical Outcomes in Patients with Symptomatic Knee Osteoarthritis Following Arthroscopic Lavage: A Randomized,...
Published 2012-01-01“…To evaluate the effect of intraarticular injections of polymerized collagen after arthroscopic lavage on inflammation and clinical improvement in patients with knee osteoarthritis (OA). Methods. Patients (n=19) were treated with 6 intraarticular injections of 2 mL of polymerized collagen (n=10) or 2 mL of placebo (n=9) during 3 months. …”
Get full text
Article -
691
Nissen-Sleeve procedure versus laparoscopic Roux-en-Y gastric bypass in patients with morbid obesity and gastro-oesophageal reflux disease: protocol for a non-inferiority randomise...
Published 2022-06-01“…The aim of this study is to compare effectiveness of Nissen-Sleeve with LRYGB.Method and analysis This is a single-centre, phase III, parallel-group randomised controlled trial in a high-volume bariatric centre in the Netherlands. A total of 88 patients with morbid obesity and GORD will be randomised to evaluate non-inferiority of Nissen-Sleeve versus LRYGB (non-inferiority margin 15%, power 80%, one-sided α 0.025, 9% drop out). …”
Get full text
Article -
692
Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and i...
Published 2025-01-01“…Active inflammatory bowel disease and anterior uveitis EAIRs were 0.8 and 0.7, respectively. 202/303 (66.7%) patients completed Week 256. 42 (13.9%) patients discontinued treatment due to TEAEs.Efficacy at Week 48 was maintained for 5 years. …”
Get full text
Article -
693
Impact of multimorbidity on long-term outcomes in older adults with non-ST elevation acute coronary syndrome in the North East of England: a multi-centre cohort study of patients u...
Published 2022-07-01“…The primary composite outcome was all-cause mortality, myocardial infarction, stroke, urgent repeat revascularisation or significant bleeding.Results Mean age was 80.9 (±6.1) years. The cohort median CCI score was 5 (IQR 4–7). …”
Get full text
Article -
694
Influence of the metabolic control in patients with type 1 diabetes on their oral health status and the need for orthodontic treatment in a group of Spanish children (aged 6–12 yea...
Published 2025-01-01“…In the group of patients with poor metabolic control, a significant increase was observed in the number of decayed teeth (1.83 ± 1.36), filled teeth (1.05 ± 0.84), and DMF-T score (3.14 ± 1.87) compared to patients with good metabolic control (1.38 ± 1.20 decayed teeth; 0.88 ± 0.86 filled teeth; DMF-T score 2.46 ± 1.87). …”
Get full text
Article -
695
-
696
-
697
-
698
-
699
-
700